Cancer moves fast…and we have to move faster

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jon M. Huntsman Sr. dared to eradicate cancer from the face of the earth. People thought he was crazy, but for someone who started out delivering fresh eggs as a boy to support his family, went on to invent and then manufacture the polystyrene egg carton, and built from scratch a $12 billion global chemical company with more than 12,000 employees, there was no holding him back. Jon was a dreamer, a risk-taker, a true visionary, and a man whose compassion for others knew no limits. He didn’t sleep. His life was dedicated to making the world a better place: a world without homelessness, a world without hunger, a world without cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Mary Beckerle
CEO, Huntsman Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.
Mary Beckerle
CEO, Huntsman Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login